For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,231 | 5,482* | 2,611 | 3,261 |
| General and administrative | 1,846 | 1,369* | 1,587 | 1,364 |
| Total operating expenses | 4,077 | 6,850 | 4,198 | 4,625 |
| Total operating loss | -4,077 | -6,850* | -4,198 | -4,625 |
| Interest income | 36 | 29* | 39 | 26 |
| Change in fair value of derivatives | 983 | 1,404* | -2,205 | -1,096 |
| Interest expense | 1,988 | 1,860* | 1,820 | 1,826 |
| Total other income (expense) | -969 | -428* | -3,986 | -2,896 |
| Net loss | -5,046 | -7,278* | -8,184 | -7,521 |
| Preferred stock dividends | 21 | -15* | 39 | 63 |
| Net loss applicable to common stockholders | -5,067 | -7,263 | -8,223 | -7,584 |
| Basic EPS | -0.08 | -0.113 | -0.13 | -0.12 |
| Diluted EPS | -0.08 | -0.113 | -0.13 | -0.12 |
| Basic Average Shares | 65,782,000 | 64,057,000 | 64,205,000 | 63,447,000 |
| Diluted Average Shares | 65,782,000 | 64,057,000 | 64,205,000 | 63,447,000 |
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)